Asenapine in the Treatment of Bipolar Depression.

ABSTRACT:

Objectives

Asenapine, a potent serotonin 7 (5-HT₇) receptor antagonist, was examined for efficacy as an antidepressant in depressed bipolar subjects. It was predicted that subjects with the genetic variant of the short form of the serotonin transporter (5HTTR) would be more likely to respond.

Experimental design

A subset of patients participating in a randomized, placebo-controlled study of the efficacy of asenapine in bipolar I depression also underwent genetic testing for the 5HTTR. Montgomery Åsberg Depression Rating Scale (MADRS) score was ≥ 26 prior to randomization to asenapine or placebo for 8 weeks. Gene testing was performed before breaking the blind.

Principal observations

Nine patients completing the study also underwent gene testing. At study en

SUBMITTER: El-Mallakh RS 

PROVIDER: S-EPMC7093720 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature